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Abstract
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition  
characterized by chronic pelvic pain related to the bladder. One phenotype of IC/BPS is 
the Hunner lesion type IC/BPS. Hunner lesion exhibits typical features such as mucosal 
ulceration, fibrosis, and severe inflammation. The tissue surrounding the Hunner lesion 
may show lymphoplasmacytic infiltrates, and mast cells are increased in the lamina 
propria. In this chapter, we discuss intravesical treatment, endoscopic treatment, and 
partial cystectomy with augmentation cystoplasty for the management of Hunner 
lesion in IC/BPS patients.
Keywords: Bladder pain syndrome, Endoscopic treatment, Hunner lesion, Interstitial 
cystitis, Intravesical treatment
1. Introduction
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a condition character-
ized by chronic pelvic pain, pressure or discomfort perceived to be related to the 
urinary bladder and is accompanied by other urinary symptoms in the absence of 
confusable diseases [1]. Interstitial cystitis was first described by Skene in 1887, 
and its definition has changed over the past 100 years. Guy Hunner was the first 
to identify the characteristic cytoscopic findings associated with bladder pain that 
were initially called Hunner’s ulcers. However, these cytoscopic findings are not 
characteristic of an ulcer and instead due to a severe inflammatory lesion; therefore, 
the term ulcer is no longer used. IC/BPS is divided into the Hunner type interstitial 
cystitis with Hunner lesion and bladder pain syndrome (BPS) without Hunner 
lesion [2]. Hunner type IC/BPS cystitis has characteristic endoscopic findings and 
distinct inflammatory histopathology, whereas BPS lacks both the endoscopic and 
histopathology findings. The Hunner lesion is described as a “circumscript, red-
dened mucosal lesion with small vessels radiating toward a central scar, with fibrin 
deposit or coagulum” and a “velvet red patch that looks like carcinoma in situ” 
(Figure 1) [1].
During cystoscopic examination, it is crucially important to watch the bladder 
mucosa from the early phase of bladder filling, because Hunner lesions might be 
obscured shortly after bladder distension. Recent research has revealed significant 
differences in the demographics, clinical presentation, bladder pathology, urinary 
marker profiles, and treatment responses between patients with IC/BPS with 
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Hunner lesion and those without Hunner lesion. IC/BPS with Hunner lesions is a 
distinct inflammatory disorder characterized by epithelial denudation and frequent 
clonal expansion of infiltrating B cells, in association with biological processes 
involved in immune responses and infectious disease [3]. IC/BPS without Hunner 
lesions, however, rarely show histological changes and retain a preserved uro-
thelium. IC/BPS with Hunner lesion has an incidence of up to 7% among IC/BPS 
patients and is categorized as a separate disease from non-Hunner IC/BPS [2, 4, 5]. 
In this chapter, we discuss intravesical treatment and endoscopic treatment of the 
Hunner lesion type IC/BPS.
2. Intravesical treatment
2.1 Dimethyl sulfoxide
Intravesical instillation of dimethyl sulfoxide (DMSO) was approved by the FDA 
in 1978 as a treatment method for IC/BPS. The mechanism of action of DMSO may 
involve anti-inflammatory effects, nerve blockade, smooth muscle relaxation, and 
collagen inhibition [6]. In the American Urological Association (AUA) guidelines, 
intravesical DMSO may be used for symptoms refractory to conservative measures 
or as initial treatment to address severe symptoms as second-line treatment [7]. 
In contrast, the EAU guideline does not recommend the use of DMSO because of 
insufficient evidence. A review by Cochrane also reported that the evidence for 
treating IC/BPS with intravesical DMSO is limited [6]. In 1988, Perez-Marrero et al. 
[8] published a trial with 33 patients and found that the proportion of patients with 
subjective symptom improvement was 53% among DMSO-injected patients com-
pared with 18% in the placebo group. Since then, several single-arm studies have 
been reported, and most studies have confirmed the 61–95% of therapeutic effect 
of DMSO in patients who did not respond to medication or hydrodistension.
A multicenter, randomized, placebo-controlled trial examining DMSO com-
pared with placebo in 96 patients was recently published in Japan in 2021 [9]. The 
mean O’Leary-Sant Interstitial Cystitis Symptom Index (ICSI) score at week 12 
decreased by −5.2 in the DMSO group compared with a decrease by −3.4 in the pla-
cebo group, with a statistically significant difference between the groups. Although 
the O’Leary-Sant Interstitial Cystitis Problem Index (ICPI), number of frequency, 
Figure 1. 
Cystoscopic findings of Hunner lesion.
3
Management of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients
DOI: http://dx.doi.org/10.5772/intechopen.100052
mean voided volume, and maximum voided volume showed significant improve-
ment in the DMSO group compared with placebo group, there was no significant 
difference in the pain score between the two groups at 12 weeks. In this study, 
Hunner lesions were confirmed by cystoscopy at baseline in 86% of all patients. The 
authors speculated that the high incidence of Hunner lesions may have contributed 
to the clinical efficacy of DMSO. Although it was a small study, another study 
compared the efficacy of DMSO treatment between patients with and without 
Hunner lesion, and DMSO intravesical instillation showed a significant therapeutic 
effect only in IC/BPS patients with Hunner lesion. These findings suggest that IC/
BPS with Hunner lesion and IC/BPS without Hunner lesion have different charac-
teristics, and intravesical DMSO treatment with strong anti-inflammatory effects 
may play a greater role in Hunner lesion type IC/BPS.
2.2 Hyaluronic acid
Hyaluronic acid (HA) is a component of the glycosaminoglycan (GAG) layer 
of the bladder and is used to repair the GAG layer. A previous study synthesis in an 
inflammatory model of IC/BPS indicated that the mechanism of action involves 
modulation of urothelial permeability and stimulation of GAG [10]. HA is used at a 
concentration of 0.8% for intravesical instillation treatment for IC/BPS. In a previ-
ous study in which intravesical HA was administered for 4 weeks with monthly 
instillation for 6 months in patients with refractory IC/BPS, the response rate at 
12 weeks was 71% and was maintained well until 20 weeks. In a study comparing 
HA and heparin intravesical instillation after hydrodistension, the therapeutic 
effect of severe IC/BPS patients was maintained longer in patients who received HA 
instillation than those who received heparin.
2.3 Chondroitin sulfate
Chondroitin sulfate (CS) is a glycoprotein and a component of the GAG layer of 
bladder mucosa. Commercially available CS products include iAluRil (Juno, AK), 
Uracyst (Galen, UK), and Uropol (Galen). Nickel et al. [11] performed a multicenter, 
randomized, double-blind study in which 20 ml of 2% CS or an inactive control solu-
tion were injected weekly for 8 weeks for female patients with IC/BPS. The propor-
tion of patients with moderate or marked improvement at 11 weeks was 38.0% in the 
CS group and 31.3% in the control group; CS treatment in IC/BPS patients showed 
minor improvements in IC/BPS-related symptom and pain. In another recent report, 
intravesical CS was found to be superior to intravesical HA in terms of frequency, 
nocturia and ICPI in patients with BPS/IC during the 6 months of follow-up [12]. In 
refractory IC/BPS patients, the combination of 1.6% HA and 2.0% CS maintained 
improvement in symptoms for up to 3 years, indicating that the combination treat-
ment might be more effective than the monotherapy [13].
3. Transurethral surgical ablation
3.1 Symptom control
If a Hunner lesion is confirmed by cystoscopy, transurethral surgical treat-
ment should be performed. In 1971, Kerr et al. [14] first performed transurethral 
resection on a female patient with Hunner lesion who reported symptom relief for 
1 year. In 2000, Peeker et al. [15] reported that 40% of patients who underwent 
transurethral resection of Hunner lesion had symptomatic improvement; the 
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remission rate was 34.5%, and patients remained in remission for 3 years after 
resection. In addition, Lee et al. [16] reported that combined hydrodistension 
and transurethral resection treatment increased bladder capacity and reduced the 
frequency of micturition and pain. Although the transurethral ablation methods, 
such as fulguration, coagulation, or resection of Hunner lesion, differ according to 
various studies, the pain visual analogue scale (VAS) significantly improved after 
transurethral ablation.
We performed a prospective, observational study of 72 patients with IC/BPS 
with Hunner lesion who underwent transurethral ablation and followed patients for 
3 years [17]. At one month after surgery, the mean number of frequency and mean 
number of urgency episodes decreased sharply to 5.5 times and 9.4 times, respec-
tively. Over the 12-month follow-up period, the number of frequency, urgency and 
VAS pain score increased compared with immediately after primary ablation treat-
ment; however, these indices were all significantly better, even after 12 months.
3.2 Characteristics of recurrence
As the extent of Hunner lesion increases, the patient’s pain and urinary symp-
toms tend to become more severe. The ICSI and ICPI and the maximum blad-
der capacity are significantly associated with the extent of Hunner lesion [18]. 
Nevertheless, it seems unlikely that patients with multiple Hunner lesion or a wider 
extent of Hunner lesion are more likely to show recurrence. Akiyama et al. [18] 
performed hydrodistension with fulguration for Hunner lesion and evaluated the 
outcome according to the extent of Hunner lesion; the authors found that the extent 
of Hunner lesion did not predict the need for repeat hydrodistension/fulguration. 
In our previous study, we were also unable to identify predictive factors related to 
recurrence. Lower maximal cystometric capacity [odds ratio (OR) 1.01, 95% CI 
1.001–1.013; P = 0.017] was the only predictive factor related to early recurrence 
within 12 months, but sex, presence of previous hydrodistension, and number of 
Hunner lesions did not affect early recurrence [17]. Han et al. [19] also examined 
the recurrence pattern and predictors of Hunner lesion; the number of Hunner 
lesions had no effect on recurrence and only the Pelvic Pain and Urgency/Frequency 
Patient Symptom Scale (PUF) bother score (OR 1.142, 95% CI 1.016–1.284, 
P = 0.026) was a predictor related to recurrence of Hunner lesion. A PUF bother 
score greater than or equal to 7.5 was identified as the predictive cut-off value for 
recurrence, with a ROC area of 0.690 (sensitivity: 67.9%, specificity: 62.5%). In 
summary, the predictors of Hunner lesion recurrence have not yet been clearly 
identified; recurrence or progression does not appear to be faster in patients with 
multiple Hunner lesions and severe symptoms at the time of initial diagnosis.
One study evaluated the recurrence patterns of Hunner lesion after transurethral 
ablation and showed that 21.8% of Hunner lesions recurred in the previous ablation 
site, 18.8% recurred in a de novo site, and 59.4% recurred in both previous and de 
novo sites [19]. We analyzed the recurrence pattern through prospectively collected 
data of IC/BPS patients with Hunner lesion who underwent transurethral ablation 
(data not yet published). In our cases, Hunner lesion recurred in 120 of 210 patients 
with a median follow-up of 32 months. Among patients with a first recurrence, 
the proportion of patients with recurrence at the previous ablation site was 50.8% 
(n = 61), while 6.7% (n = 8) had recurrence of a new lesion, and 42.5% (n = 51) had 
recurrence at both previous and new sites. Overall, 90% of patients had recurrence 
around the previous ablation site, and less than 7% showed recurrence at a new 
site. Endoscopic treatment for Hunner lesion shows good efficacy in alleviating 
symptoms for a specific period of time after the procedure, but ultimately does not 
prevent Hunner lesion recurrence. This is considered a natural course of IC/BPS with 
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Hunner lesion disease with the characteristics of pancystitis. To prevent recurrence, 
the role of postoperative medication or intravesical treatment should be investigated. 
A recent pilot study reported that hydrodistension with fulguration of Hunner lesion 
plus maintenance DMSO therapy prolonged the recurrence-free time in patients 
with IC/BPS with Hunner lesion [20].
3.3 Does repeat treatment reduce recurrence?
One question regarding the recurrence of Hunner lesions is whether endoscopic 
treatment helps to suppress recurrence. However, current research indicates this 
may not be the case. In a 30-month prospective study of IC/BPS with Hunner 
lesion treatment naïve patients, the median recurrence-free time after the first 
endoscopic ablation of Hunner lesion was 12.0 ± 1.6 months (95% CI; 8.9–15.1). 
After the second endoscopic ablation, the median recurrence-free time was 
18.0 ± 5.1 months (95% CI; 8.0–28.0), which was slightly increased, but the differ-
ence was not statistically significant (p = 0.15) [17]. Nevertheless, if Hunner lesion 
recurs, repeat ablation should be performed. Repeated endoscopic ablation does 
not lower the recurrence rate, but it is the only way to significantly reduce pain and 
improve quality of life in a less invasive manner.
3.4  Which endoscopic treatment, transurethral resection or coagulation, can 
further reduce recurrence?
Prominent ulcerations are observed in the histology of Hunner lesion, which 
may be covered by fibrin mixed with inflammatory cells, in particular neutrophils. 
The lesions are often wedge-shaped and involve the superficial part of the lamina 
propria, often extending into the muscularis mucosae. Thus, deep biopsies includ-
ing bladder muscle are required, since the disease process involves superficial as well 
as deeper layers of the bladder wall [4]. Many symptoms and findings in IC/BPS 
with Hunner lesion may be ascribed to the release of mast cell–derived factors. Mast 
cells are often observed near nerves, and functional evidence suggests innervation 
of these cells. As a hypothesis that has been accepted so far, transurethral ablation 
might be the removal of intramural nerve endings engaged in the inflammatory 
process [21–23].
Whether transurethral resection of Hunner lesion is capable of disease control 
compared with coagulation/fulguration and prevents recurrence of Hunner lesion 
is an important question. A randomized controlled study was conducted to compare 
the therapeutic effect between transurethral resection and coagulation of Hunner 
lesion in 126 patients with IC/BPS [24]. The primary endpoint was the difference 
in recurrence-free time between the two surgical methods, and the secondary 
outcomes were voiding symptoms, pain level, and risk factors for recurrence. The 
median duration of follow-up was 11.0 months. There were no differences in the 
recurrence-free time between the treatment groups: 12.2 months (95% confidence 
interval [CI], 11.1–17.6) for the transurethral resection group and 11.5 months 
(95% CI, 9.03–16.1; p = 0.735) for the transurethral coagulation group. In addition, 
after both procedures, the mean daytime frequency, nocturia, urgency episodes, 
ICSI, ICPI, PUF symptom scale, and VAS for pain all improved significantly 
compared with baseline; however, there were no differences between the groups 
over 12 months. The type of surgery, age, number of Hunner lesions, and maximal 
cystomteric capacity were not associated with the risk of recurrence. In safety 
analysis, in cases treated with transurethral resection, the incidence of bladder 
injury was 7.9%, which was slightly higher than that among patients treated with 
coagulation, which was 3.4%. Our findings did not suggest that one procedure was 
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superior to the other with regard to delaying recurrence. The choice of treatment 
did not affect the recurrence rate and produced comparable results, which may be 
because the ultimate peripheral denervation acted as the same thermal effect in 
both treatments.
3.5  Is it helpful to perform concurrent hydrodistension before transurethral 
ablation?
Some studies have suggested that concurrent hydrodistension with transure-
thral ablation may be helpful for symptom improvement [16, 18, 25]. However, 
the simultaneous performance of hydrodistension causes difficulties in complete 
removal of the Hunner lesion. Hydrodistension obscures the boundaries of the 
Hunner lesion, which are clearly identified through cystoscopy, and bleeding 
related to hydrodistension interferes with the field of surgical view. We believe that 
good efficacy can be maintained only with transurethral resection or coagulation of 
Hunner lesion without hydrodistension.
3.6 Technique of transurethral coagulation and resection of Hunner lesion
To coagulate or resect the Hunner lesion, the most important first step is to 
demarcate the lesion with the cautery before full bladder distension. Complete 
coagulation of the inside Hunner lesion of the boundary should then be performed. 
If starting from the inside of the lesion and working outward, reactive erythema 
spreads outward and obscures the original boundary of the lesion. In the case of 
transurethral resection, it is effective to use a bipolar loop. During the resection, 
resection should be performed as deeply as possible to the muscle layer using a 
cutting current. However, bladder damage can easily occur because the bladder 
wall of Hunner lesion is thin and friable. To prevent bladder injury, the quantity 
of irrigation fluid should be kept constant through suction attached to the outer 
sheath. Using this approach, the risk of bladder damage can be reduced by prevent-
ing the overdistension of bladder. Nevertheless, when it is difficult to complete 
resect the Hunner lesion or when the surgeon does not have extensive experience for 
transurethral resection, transurethral coagulation alone may be enough to control 
Hunner lesions.
4. Reconstructive surgery
Partial or complete cystectomy, augmentation cystoplasty, and urinary diver-
sion are options indicated by the AUA and East Asian guidelines when all other 
therapies have failed [1, 7]. Rossberger et al. [26] found that reconstructive surgery 
resulted in the resolution of symptoms in 94% of patients with refractory IC/BPS 
with Hunner lesion. Patients with IC/BPS with Hunner lesion had a significantly 
smaller bladder capacity and benefited from reconstructive surgery compared 
with patients without Hunner lesion. We retrospectively analyzed 40 patients who 
underwent augmentation ileocystoplasty with supratrigonal cystectomy in patients 
with refractory IC/BPS with Hunner lesion [27]. After augmentation with supra-
trigonal cystectomy, significantly decreased pain and frequency and significantly 
increased bladder capacity were observed. Treatment failure was defined as the 
persistence of symptoms after surgery or a less than 30% reduction in ICSI from 
baseline, which accounted for 20% (8/40) of patients. Two of the patients had 
recurrent Hunner lesion around the bladder neck and additional endoscopic abla-
tion was performed, while the remaining patients maintained oral medication [27]. 
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There may be concerns about major complications after reconstructive surgery; 
however, most complications were minor and managed conservatively. Although 
six patients had vesicoureteral reflux after surgery, there was no deterioration of 
the upper urinary tract, so no additional treatment was required. Five patients 
received intermittent catheterization because they were unable to void after 
surgery, but the discomfort of catheterization was not considered a significant 
problem due to improvement in pain [27].
5. Conclusion
Although there is no definite treatment for IC/BPS, endoscopic treatment can 
be considered for Hunner lesion type IC/BPS. To confirm the presence of Hunner 
lesion, cystoscopy should be performed in patients with suspected IC/BPS. When 
performing cystoscopy, the bladder should not be inflated too much to prevent 
false-positive findings or bleeding due to mucosal fissure and to accurately diagnose 
Hunner lesion. Various intravesical therapies, including HA, CS, and DMSO, have 
been used for IC/BPS and are more effective in terms of anti-inflammatory effects 
and GAG layer replenishment in patients with Hunner lesion than patients without 
Hunner lesion. Overall, endoscopic ablation for Hunner lesion is an effective and 
minimally invasive treatment for patients with Hunner lesion type IC/BPS; this 
treatment strategy significantly reduces pain and improves voiding symptoms. 
Mucosal cracks that occur during hydrodistension are not real Hunner lesion, and 
we do not recommend performing hydrodistension first during endoscopic ablation. 
Repeated ablation does not suppress recurrence but does not reduce the therapeutic 
efficacy. There are various methods for endoscopic ablation; the main methods are 
coagulation or resection of Hunner lesion, and both are good treatment modalities 
to relieve the symptoms of Hunner lesion IC/BPS and improve quality of life. IC/
BPS with Hunner lesion is a progressive disease, and it is necessary to establish a 
treatment protocol such as adjuvant intravesical treatment to reduce the risk of 
recurrence after transurethral ablation.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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